The Austrian company Mezzanine Management reported that its fund AMC Capital IV sold the Croatian clinical research company Optimapharm to the American asset management company Rohatyn Group. In October 2018, Mezzanine Management secured debt and equity financing worth €10m to acquire a minority stake in Optimapharm through AMC Capital IV, marking its first investment in Croatia. In early 2018, they took over a Czech clinical research company called MKS Research, and opened new offices in the United Kingdom and Hungary.
They currently have offices open in twelve countries. The investment has produced strong returns for AMC Capital IV, which saw profits triple as the business grew organically and through three additional acquisitions. The number of Optimapharm offices has grown from ten to fifteen due to the growing number of customers across Europe.
